Rehabilitation Intervention for COPD Combined With Cardiovascular and Cerebrovascular Diseases

Rehabilitation Intervention for COPD Combined With Cardiovascular and Cerebrovascular Diseases

Firstly, to screen out the high-risk population of COPD combined with cardiovascular and cerebrovascular diseases, COPD with cardiovascular and make a diagnosis. Then, to evaluate the therapeutic effect of Pulmonary rehabilitation exercise and usual care for three months. And finally, to build a trinity model of rehabilitation management of COPD patients. The objective of this project is to establish and promote the application of diagnostic and treatment norms.

Firstly, to screen out the high-risk population of COPD combined with cardiovascular and cerebrovascular diseases, COPD with cardiovascular and make a diagnosis. Then, participants were randomized (1:1) to either the optimized or routine group via a computer-generated random number table. The Routine Care Group received treatment for three months and follow-up with medications prescribed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report. The Pulmonary Rehabilitation Care Group received the Pulmonary rehabilitation exercise and usual care for three months. Next, Observe the changes in the improvement of acute exacerbation frequency (times/year/person)，CAT Scoring and St. George's Respiratory Questionnaire (SGRQ), as well as lung ventilation and diffusion function of the two groups of patients one year after the intervention. And finally, to build a trinity model of rehabilitation management of COPD patients.

Inclusion Criteria:

1. Committed to adhering to the study protocol and cooperating with the implementation of the entire research process.
2. Aged 18 years or older, regardless of gender.
3. Signed informed consent form.

Exclusion Criteria:

1. Individuals with severe mental illness.
2. Individuals assessed by medical personnel as having a disease that requires immediate hospitalization or a severe, uncontrollable condition that is life-threatening in the short term.
3. Women who are pregnant, breastfeeding, or using inappropriate contraception methods.
4. Individuals who refuse to cooperate with follow-up questionnaires or specimen collection.
5. Patients currently participating in other interventional clinical drug trials.